Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres.

Cimerli (ranibizumab-eqrn) - Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG

Vabysmo (faricimab-svoa) - Roche

Beovu (brolucizumab-dbll) - Novartis

Lucentis (ranibizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/40973776

Ahmed Yosef; Christiana Dinah; Clare Dadswell; Hannah Tebbs; Kate Kelley; Kirsty Luckham; Lindsay Claxton; Nichole Taske; Noemi Lois; Philip I Burgess; Syed Mohiuddin

Sep 20, 2025